Cite
HARVARD Citation
Bartsch, R. et al. (2023). P014 Interim analysis of ELEANOR (n = 200): a multi-national, prospective, non-interventional study (NIS) among patients with HER2+ and HR+ early breast cancer (eBC) treated with extended adjuvant neratinib. Breast. pp. S20-S21. [Online].